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Abstract
Objective—The aim of the current study is to investigate the association of polycyclic aromatic 
hydrocarbons (PAHs), a group of environmental pollutants, with diabetes mellitus. Animal studies 
link PAHs to inflammation and subsequent development of diabetes mellitus. In addition, 
occupational studies suggest that exposure to other aromatic hydrocarbons such as dioxins may be 
associated with diabetes risk in humans.
Design—We examined participants from the merged National Health and Nutrition Examination 
Survey 2001–2002, 2003–2004 and 2005–2006. Exposures of interest were eight urinary 
monohydroxy-PAHs. Our outcome was diabetes mellitus defined as a glycohemoglobin level 
(HbA1c) ≥6.5%, a self-reported physician diagnosis of diabetes or use of oral hypoglycaemic 
medication or insulin. Analyses were adjusted for age, sex, body mass index, race, alcohol 
consumption, poverty–income ratio, total cholesterol and serum cotinine.
Results—We observed a positive association between urinary biomarkers of 1 and 2-
hydroxynapthol, 2-hydroxyphenanthrene and summed low molecular weight (LMW) PAH 
biomarkers, and diabetes mellitus. Compared with participants with summed LMW PAH 
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biomarkers in the lowest quartile, the multivariable-adjusted OR of diabetes mellitus among those 
in the highest quartile was 3.1 (95% CI 1.6 to 5.8).
Conclusions—Urinary biomarkers of 1 and 2-hydroxynapthol, 2-hydroxyphenanthrene and 
summed LMW PAH biomarkers are associated with diabetes mellitus in US adults 20–65 years of 
age. The association of a one-time biomarker of PAH exposure has limitations commonly 
associated with cross-sectional studies, yet is consistent with experimental animal data and is 
worthy of additional consideration.
INTRODUCTION
Recent studies have suggested that common environmental exposures affecting large 
sections of the population may be a determinant of diabetes mellitus risk.12 Polycyclic 
aromatic hydrocarbons (PAHs) are a group of environmental pollutants that feature aromatic 
rings.3–5 Major sources of PAHs include energy generation from biomass or fossil fuels, 
cigarette smoking and ingestion of grilled/smoked food.6–9
In vitro and animal studies have reported a positive association between exposure to PAHs 
and inflammation, with subsequent development of diabetes mellitus.10 Occupational 
studies have also suggested that exposure to halogenated aromatic hydrocarbons such as 
dioxins is associated with diabetes mellitus in humans.11 However, we are not aware of 
studies investigating PAH exposure in the general population and diabetes mellitus 
independent of smoking, a major source of PAHs.8 With advantages of recent nationally 
representative sample surveys and standardised data collection approaches, the objective of 
the current study has been to examine the association of eight urinary monohydroxy-PAH 
(OH-PAH) and diabetes mellitus in adults after adjusting for age, gender, race/ethnicity, 
body mass index (BMI), serum cotinine, self-reported smoking status and other potential 
confounders. We posit that exposure to PAHs prompts chronic inflammation and the 
subsequent development of insulin resistance and diabetes mellitus in humans.
Low molecular weight (LMW) PAHs (eg, naphthalene, fluorene and phenanthrene) are 
found in gaseous form in the ambient air where they are usually absorbed by inhalation. 
Higher molecular weight PAHs (eg, pyrene) are found in particulate form where they can be 
ingested, inhaled or absorbed through the skin.1213 Because metabolism and health effects 
of exposure to PAHs mixtures were found to be different from that of exposure to individual 
PAHs,14 we created a summed LMW PAH biomarker variable, indicating a graduating level 
of exposure to multiple LMW PAHs simultaneously.
RESEARCH DESIGN AND METHODS
Study population
The present study is based on merged data from the 2001–2002, 2003–2004 and 2005–2006 
National Health and Nutrition Examination Survey (NHANES). NHANES surveys were 
designed to be nationally representative of the non-institutionalised US civilian population 
by using a complex stratified multistage probability sample.15 Selection was based on 
counties, blocks, households and individuals within households, and included oversampling 
of certain groups in order to provide stable estimates of these groups. Data were collected 
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from interviews, questionnaire, examinations and laboratory tests of biological samples. The 
data have been released for public use in 2-year increments since 1999.
Urinary PAH biomarkers were only measured in a subsample of NHANES participants. The 
number of participants in each analysis depended on the outcome and missing data. For 
example, there were 3326 participants, 20–65 years of age with measured levels of all the 
eight urinary PAH biomarkers included in the current study. We excluded participants with 
missing information on serum cotinine level or other variables included in the multivariable 
model. This resulted in 2769 participants included in the summed LMW PAH-diabetes 
analyses.
Main outcome of interest: diabetes mellitus
Glycohemoglobin measurements for NHANES 2001–2002 and 2003–2004 were performed 
by the Diabetes Diagnostic Laboratory at the University of Missouri-Columbia using Primus 
CLC330 and Primus CLC 385 (Primus Corporation, Kansas City, Missouri, USA). 
Glycohemoglobin measurements for NHANES 2005–2006 were performed by the Diabetes 
Laboratory at the University of Minnesota using Tosoh A1c 2.2 Plus Glycohemoglobin 
Analyzer (Tosoh Medics, Inc., San Francisco, California, USA). Both assays use a high-
performance liquid chromatography (HPLC) system. Diabetes was defined as HbA1c level 
≥ 6.5% (39 mmol/mol), a self-reported physician diagnosis of diabetes or current use of oral 
hypoglycaemic medication or insulin.16
Main exposure: urinary levels of monohydroxy-PAH
Urine specimens were processed, stored and shipped to the Division of Environmental 
Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease 
Control and Prevention for analysis. The specific analytes measured in this method are 
monohydroxy-PAHs (OH-PAH).17 The procedure involves enzymatic hydrolysis of urine, 
extraction, derivatisation and analysis using capillary gas chromatography combined with 
high-resolution mass spectrometry (GC-HRMS). This method uses isotope dilution with 
carbon-13 labelled internal standards. Ions from each analyte and each carbon-13 labelled 
internal standard are monitored, and the abundances of each ion are measured. The ratios of 
these ions are used as criteria for evaluating the data. By evaluating these analytes in urine, a 
measurement of the body burden from PAH exposure is obtained.
Eight urinary OH-PAH analytes—1-hydroxynaphthalene, 2-hydroxynaphthalene, 2-
hydroxyfluorene, 3-hrdroxyfluorene, 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-
hydroxyphenanthrene and 1-hydroxypyrene—are consistently available in NHANES 2001–
2006.
All analytes were measured in the same unit (ng/L). Urinary OH-PAH were corrected for 
creatinine concentration, a urinary marker of kidney function to adjust for urinary dilution.18 
Urinary levels of OH-PAH (ng/L) were divided by urinary creatinine level (mg/dL) 
multiplied by 0.01, that is, [(ng/L) ÷ (mg/dL*0.01)], and expressed as nanogram per gram of 
creatin-ine (ng/g creatinine).
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Information on age, gender, race/ethnicity, alcohol intake, income and cigarette smoking 
were obtained from a standardised questionnaire during a home interview. Income–poverty 
ratio was used as a measure of the socioeconomic status. The Department of Health and 
Human Services’ poverty guidelines were used by NHANES to calculate this ratio. Smoking 
status was categorised into never smokers (smoked <100 cigarettes during their lifetime), 
former smokers (smoked ≥100 cigarettes during their lifetime and currently not smoking) 
and current smokers (smoked ≥100 cigarettes during their lifetime and currently smoking). 
Information on anthropometric, physical and laboratory components were obtained during 
the medical examination centre examination.
BMI was calculated as weight in kilograms divided by height in metres-squared. Total 
cholesterol was measured enzymatically. Serum cotinine was measured by isotope dilution-
HPLC atmospheric pressure chemical ionisation tandem mass spectrometry (ID HPLC-
APCI MS/MS).
Statistical analysis
Our first step involves exploratory data analyses to shed light on the underlying distributions 
of the variables of interest and examine outliers. We ran linear regression models to 
calculate the multivariable change and 95% CI in log-transformed HbA1c (%) for each of 
the log-transformed urinary OH-PAH. By taking a log transformation, the distribution of the 
residuals was improved when compared with the residual distribution of the untransformed 
variables. In the next step, we ran logistic regression models to calculate the multivariable 
OR and 95% CI of diabetes mellitus, for each higher urinary OH-PAH quartile by using the 
lowest quartile as the referent. Variables were included in the model if they satisfied two 
conditions: first, a plausible association with the main outcome; and second, if the per cent 
change of the OR after adjusting for the potential confounder was over 10%. Accordingly, 
final models were adjusted for age (years), sex (male/female), ethnicity (non-Hispanic 
White, non-Hispanic Black, all others), poverty–income ratio (<1, ≥1), alcohol consumption 
(yes, no), BMI (normal, overweight, obese), total cholesterol (mg/dL) and serum cotinine 
(ng/mL).
To further ensure that the association was parallel for subgroups, we performed subgroup 
analyses by gender, race/ethnicity, BMI and smoking categories. Sample weights that 
account for the unequal probabilities of selection, oversampling and non-response in the 
NHANES survey were applied for all analyses. Analyses were conducted using SAS (V.9.3, 
SAS Institute, Cary, North Carolina, USA) software. SEs were estimated using the Taylor 
series linearization method.
RESULTS
Table 1 presents the baseline characteristics of the study population. The study population 
was primarily non-Hispanic White (71.7%). Normal weight, overweight and obese BMI 
categories were equally distributed. Approximately one-half (50.2%) were never cigarette 
smokers. The mean value of serum cotinine level was 74.7 ng/mL. Diabetes mellitus was 
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reported in 7.5% of the study population. Sample sizes, weighted means and selected 
percentile of urinary levels of OH-PAH used in the final analysis are presented in the online 
supplementary table. Compared with those who were included in the final sample, 
participants who were excluded because of missing data were similar with respect to basic 
information listed in table 1, as well as the exposure and the outcome of interest.
The main estimates of the study are presented in table 2. Urinary levels of 1-
hydroxynaphthalene, 2-hydroxynaphthalene, 2-hydroxyphenanthrene and summed LMW 
biomarkers were positively associated with diabetes mellitus in the multivariable adjusted 
models. Our subsequent analyses (results not shown in the table) examined the linear 
association between log-transformed HbA1c (%) and log-transformed urinary OH-PAH. 
Only levels of 2-hydroxynaphthalene (β=0.005), 2-hydroxyfluorene (β=0.007) and 2-
hydroxyphenanthrene (β=0.007) were statistically significant (p<0.05) in the multivariable-
adjusted linear regression model.
Next to examine effect modification, we performed subgroup analyses by major 
characteristics of the study population (table 3). Overall, higher levels of PAH biomarkers 
were positively associated with diabetes within the stratified subgroups; however, we found 
no appreciable variation among subgroups of gender, race/ethnicity, BMI or smoking. p 
interaction values for cross-product terms between urinary OH-PAH levels and stratifying 
variables were all >0.20.
DISCUSSION
Studying PAHs and diabetes mellitus in a relatively large multi-ethnic sample of US adults, 
we found evidence that higher urinary levels of 1-hydroxynaphthalene, 2-
hydroxynaphthalene, 2-hydroxyphenanthrene and summed LMW biomarkers were 
positively associated with diabetes mellitus, independent of potential confounders. In 
addition, urinary levels of 2-hydroxynapthalene, 2-hydroxyfluorene and 2-
hydroxyphenanthrene showed positive associations with HbA1c. Researchers have 
examined PAHs directly in the blood and tissues of experimental animals; however, these 
methods have not been widely used in humans due to the high costs and the limited clinical 
significance of testing. The most commonly used biomarkers of PAH exposure are urinary 
OH-PAH biomarkers and PAH-DNA adducts. Urinary OH-PAH biomarkers have been 
found to correlate well with low background levels of exposure to PAHs.19
Previous studies have reported a role of chronic exposure to PAHs in the development of 
oxidative stress.20 Oxidative stress plays a major role in the pathogenesis of diabetes 
mellitus.21 Studies have also reported a positive association between PAH exposure and 
inflammation,22–24 a strong risk factor for obesity, insulin resistance and subsequent 
development of diabetes mellitus.25 Chronic exposure to PAHs was also found to induce 
intestinal inflammation with subsequent increase in the risk of type 2 diabetes in animals.10 
Besides its suggested inflammatory effects, PAHs cause disruption of the endocrine system, 
with changes in plasma oestrogen concentrations in rats.26 Oestrogen participates in glucose 
homeostasis by modulating the expression of genes that are involved in insulin sensitivity 
and glucose uptake.2728
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The strengths of this study include the relatively large multi-ethnic sample of US adults, the 
high quality of NHANES laboratory and data collection methods and the ability to adjust for 
confounders. In addition, we believe this is the first study to investigate the association 
between PAHs and diabetes in the general US population, adjusting for potential 
confounders including serum cotinine, an objective measure of cigarette smoke exposure. 
Serum cotinine is considered a more precise measure of exposure to cigarette smoking 
compared with self-reported smoking status2930 and is also considered a useful biomarker of 
secondhand smoke exposure.31
The study has several limitations. The cross-sectional nature of NHANES does not allow us 
to draw temporal or causal inferences regarding the relationship between PAHs and diabetes 
mellitus. Urinary PAH measurements reflect recent exposure if there are great differences 
between the current exposure sources and the past exposure sources for each subject. 
However, these biases are likely to be non-differential biases,32 which would bias the 
association towards the null. In addition, because NHANES does not collect information to 
identify the type of diabetes, we cannot distinguish type 1 and type 2 diabetes. However, 
based on the population distribution of the two diabetes mellitus phenotypes, we believe that 
the majority of diabetes subjects in our sample have type 2 diabetes mellitus. It is also 
possible that diabetes mellitus causes higher PAH concentrations retained in the body due to 
subnormal kidney functions, a reverse causation that we address but that cannot be ruled out 
in prevalence data.
In conclusion, urinary biomarker levels of LMW PAHs were found to be positively 
associated with diabetes mellitus, independent of potential confounders and consistent with 
emerging toxicology data. Both PAH exposure and diabetes mellitus are highly prevalent in 
the USA. Considering the limitations of our study, further prospective studies are necessary 
to determine the causal relationship.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What this paper adds
▶ Occupational and animal studies link polycyclic aromatic hydrocarbons 
(PAHs) to inflammation and subsequent development of diabetes mellitus.
▶ It is not clear whether exposure to PAHs in the general population is 
associated with diabetes mellitus risk in humans independent of cigarette 
smoking.
▶ We report a positive association between urinary biomarkers of 1 and 2-
hydroxynapthol, 2-hydroxyphenanthrene and summed low molecular weight 
PAH biomarkers, and diabetes mellitus in US adults 20–65 years of age.
▶ Considering the limitations of our study, further prospective studies are 
necessary to determine the causal relationship.
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Table 1
Baseline characteristics of the study population with measured urinary levels of OH-PAH (n=2769)
Characteristics Mean values±SE of mean or sample size (weighted percentages)*
Female (%) 1418 (49.8)
Age (years) 41.0±0.3
Race/ethnicity (%)
 Non-Hispanic Whites 1374 (71.7)
 Non-Hispanic Blacks   584 (10.9)
 Others   811 (17.4)
Education categories (%)
 Less than high school   667 (14.5)
 High school   650 (24.9)
 Above high school 1452 (60.6)
Below poverty level (%)   493 (12.9)
Smoking categories (%)
 Never 1443 (50.2)
 Former smokers   584 (21.6)
 Current smokers   741 (28.2)
Alcohol drinking (%)
 Yes 1993 (76.2)
Body mass index (%)
 Normal weight (<25.0 kg/m2)   861 (34.3)
 Overweight (25.0–29.9 kg/m2)   925 (31.6)
 Obese (>30.0 kg/m2)   983 (34.1)
Serum cotinine (ng/mL) 74.7±4.0
Total cholesterol (mg/dL) 201.2±1.3
Diabetes (%)   257 (7.5)
*
Data for the USA based on the National Health and Human Examination Survey, 2001–2006.
OH-PAH, monohydroxy polycyclic aromatic hydrocarbon.
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Table 3
Logistic regression: association of urinary OH-PAH (ng/g creatinine)* and diabetes mellitus by 
sociodemographic characteristics
Subgroups
Multivariable OR of diabetes mellitus (95% CI)
Summed urinary levels LMW PAH biomarkers 1-Hydroxypyrene
Gender†
 Female 1.2 (0.9 to 1.8) 1.0 (0.8 to 1.3)
 Males 1.5 (1.1 to 1.9) 1.2 (1.0 to 1.5)
Race/ethnicity†
 Non-Hispanic White 1.4 (1.1 to 1.8) 1.1 (0.9 to 1.4)
 Non-Hispanic Black 1.1 (0.8 to 1.4) 1.0 (0.7 to 1.4)
 All others 1.5 (0.9 to 2.6) 1.4 (1.0 to 1.9)
Body mass index‡
 <30 kg/m2 1.2 (0.9 to 1.7) 1.2 (0.9 to 1.4)
 ≥30 kg/m2 1.4 (1.1 to 1.9) 1.1 (0.8 to 1.4)
Smoking†
 Never smokers 1.3 (1.0 to 1.7) 1.1 (0.8 to 1.4)
 Former smokers 1.4 (1.0 to 2.1) 1.2 (0.9 to 1.6)
 Current smokers 2.2 (1.1 to 4.5) 1.3 (0.9 to 1.9)
Data for the USA based on the National Health and Human Examination Survey, 2001–2006.
*
Urinary OH-PAH values used were log-transformed.
†
Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty–income ratio (<1, ≥1), 
alcohol drinking (yes, no), BMI (normal, overweight, obese), total cholesterol (mg/dL) and serum cotinine (ng/mL), except for stratified variables.
‡
Adjusted for age (years), sex (male, female), ethnicity (non-Hispanic White, non-Hispanic Black, all others), poverty–income ratio (<1, ≥1), 
alcohol drinking (yes, no), BMI (kg/m2), total cholesterol (mg/dL) and serum cotinine (ng/mL), except for stratified variables.
BMI, body mass index; LMW, low molecular weight; OH-PAH, monohydroxy polycyclic aromatic hydrocarbon.
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